z-logo
Premium
Glomerular Filtration at the Early Stage of Diabetes
Author(s) -
Nakamoto Hiroshi,
Yada Toyotaka,
Ogasawara Yasuo,
Kajiya Fumihiko
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.664.17
Subject(s) - diabetes mellitus , renal function , glomerular hyperfiltration , medicine , chemistry , endocrinology , albumin , diabetic nephropathy
There is known to be glomerular hyperfiltration in a rat at the early stage of diabetes. This has not been studied well so far by visualisation due to its difficulty in gaining access. The purpose of this study is to visualise and evaluate glomerular filtration quantitatively under in‐vivo conditions in a rat at the early stage of diabetes. Diabetes was induced by tail vein shot of streptozotcin (50mg/kg) to Wistar rats in 8 weeks. Under Sevoflurane inhalation anaesthesia, a left kidney was exposed and a tiny window (2×2 mm 2 ) was peeled from its surface for observation. We visualised glomerular filtration by multiphoton confocal microscopy (Leica SP2) 4 to 5 seconds after administering Texas Red conjugated various seizes of dextrans (3k, 10k, 40k and 70k Da). Filtration was finished within 10 seconds. We also examined the pretreatment effects of C‐peptide in diabetic rats. Peak Intensity change of the filtrates was analysed afterwards from the record. Peak values were normalised against 3k Da dextran trial. We found that there is a greater leakage of larger particles (40k and 70k Da) in diabetic rats (n=8) by 30% than in normal rats (n=8). Albumin has close molecular weight about 66k Da. C‐peptide ameliorated this leakage to the level of normal rats (n=8)(all p<0.05). Glomerular filtration was successfully visualised in an early diabetic rat. There is a way to ameliorate leakage of larger particles due to diabetes with C‐peptide.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here